This patient's symptoms of cardiomyopathy, skeletal myopathy, and hypoketotic hypoglycemia are characteristic of a primary carnitine deficiency or a defect in the carnitine shuttle system (e.g., CPT I or CPT II deficiency). This system is responsible for transporting long-chain fatty acids from the cytoplasm into the mitochondrial matrix for beta-oxidation. The impaired transport leads to lipid accumulation in tissues like muscle and heart that rely on fatty acids for energy.

During fasting, high glucagon levels lead to the phosphorylation and inactivation of acetyl-CoA carboxylase (ACC). This reduces the production of malonyl-CoA. Malonyl-CoA is a potent inhibitor of carnitine palmitoyltransferase I (CPT-I), the enzyme that transports fatty acids into the mitochondria. By inhibiting ACC, malonyl-CoA levels fall, which relieves the inhibition on CPT-I and allows for the robust transport and oxidation of fatty acids.

The patient was most likely prescribed a statin (e.g., atorvastatin, simvastatin), which is a first-line agent for lowering LDL cholesterol. Statins are competitive inhibitors of HMG-CoA reductase, the rate-limiting enzyme in the de novo synthesis of cholesterol. By reducing hepatic cholesterol synthesis, statins cause an upregulation of LDL receptors on the surface of hepatocytes, leading to increased clearance of LDL from the circulation.

The clinical presentation of tendon xanthomas, premature cardiovascular disease, and markedly elevated LDL cholesterol is classic for familial hypercholesterolemia (FH). This is an autosomal dominant disorder most commonly caused by mutations in the LDL receptor gene. Defective LDL receptors impair the clearance of LDL particles from the circulation, leading to their accumulation and deposition in tissues like tendons and arteries.

During prolonged starvation (after several days), the liver produces large quantities of ketone bodies (acetoacetate and beta-hydroxybutyrate) from fatty acid oxidation. The brain, which cannot use fatty acids for fuel, adapts to use ketone bodies as its primary energy source. This adaptation is crucial for 'sparing' protein, as it reduces the need for gluconeogenesis from amino acids and thus preserves muscle mass.

This presentation is classic for Type I hyperlipoproteinemia (familial chylomicronemia syndrome), an autosomal recessive disorder caused by a deficiency in either lipoprotein lipase (LPL) or its cofactor, apolipoprotein C-II. LPL is responsible for hydrolyzing triglycerides within chylomicrons and VLDL in the capillary beds. Its deficiency leads to the massive accumulation of chylomicrons in the plasma, causing extremely high triglyceride levels, pancreatitis, and eruptive xanthomas.

Hypoglycin A, the toxin in unripe ackee fruit, is metabolized to methylenecyclopropylacetyl-CoA (MCPA-CoA). This metabolite irreversibly inhibits several acyl-CoA dehydrogenases, key enzymes in the beta-oxidation of fatty acids. The inhibition of beta-oxidation prevents the production of acetyl-CoA, NADH, and FADH2 from fats, leading to hypoketotic hypoglycemia as the body cannot generate alternative fuels or support gluconeogenesis during fasting.

The patient's presentation is characteristic of Zellweger syndrome, a peroxisomal biogenesis disorder. Peroxisomes are responsible for the initial beta-oxidation of very-long-chain fatty acids (VLCFAs). In disorders like Zellweger syndrome, defective peroxisomes lead to the accumulation of VLCFAs in tissues and plasma, causing severe neurologic deficits and organ dysfunction.

Lecithin-cholesterol acyltransferase (LCAT) is an enzyme found in the plasma that is associated with HDL particles. It is activated by ApoA-I, the primary apolipoprotein on HDL. LCAT catalyzes the formation of cholesteryl esters from free cholesterol and phosphatidylcholine (lecithin). This esterification is crucial for the maturation of HDL particles and for creating a concentration gradient that promotes the efflux of more cholesterol from peripheral cells.

In alcoholic ketoacidosis, the metabolism of ethanol by alcohol dehydrogenase and aldehyde dehydrogenase generates a large amount of NADH, leading to a very high NADH/NAD+ ratio. This high ratio shunts oxaloacetate towards malate and pyruvate towards lactate, depleting the substrates for gluconeogenesis (causing hypoglycemia) and the TCA cycle. The lack of oxaloacetate prevents acetyl-CoA from entering the TCA cycle, diverting it instead towards the synthesis of ketone bodies.